CA1039213A - Antibiotic ta from myxococcus xanthus - Google Patents
Antibiotic ta from myxococcus xanthusInfo
- Publication number
- CA1039213A CA1039213A CA204,155A CA204155A CA1039213A CA 1039213 A CA1039213 A CA 1039213A CA 204155 A CA204155 A CA 204155A CA 1039213 A CA1039213 A CA 1039213A
- Authority
- CA
- Canada
- Prior art keywords
- antibiotic
- methanol
- chloroform
- organisms
- micro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000863422 Myxococcus xanthus Species 0.000 title claims abstract description 28
- VQWNGCSUNKJFLW-ACPVBGRSSA-N Antibiotic TA Chemical compound CCCC1OC(=O)C(C)CC(C)CCCCC(=O)CCCC(CC)\C=C\C=C(COC)\CCC(O)C(O)CC(O)CNC1=O VQWNGCSUNKJFLW-ACPVBGRSSA-N 0.000 title claims abstract description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 81
- 230000003115 biocidal effect Effects 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 27
- 230000008569 process Effects 0.000 claims abstract description 15
- 238000002329 infrared spectrum Methods 0.000 claims abstract description 5
- 238000002835 absorbance Methods 0.000 claims abstract description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 60
- 244000005700 microbiome Species 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 12
- 108010079058 casein hydrolysate Proteins 0.000 claims description 11
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 10
- 235000012239 silicon dioxide Nutrition 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 108010076119 Caseins Proteins 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000005018 casein Substances 0.000 claims description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 6
- 235000021240 caseins Nutrition 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 238000005273 aeration Methods 0.000 claims description 5
- 238000009630 liquid culture Methods 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000008033 biological extinction Effects 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 239000012265 solid product Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 abstract description 5
- 229940088710 antibiotic agent Drugs 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229960001701 chloroform Drugs 0.000 description 20
- 238000012360 testing method Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 102000011632 Caseins Human genes 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000006916 nutrient agar Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002211 ultraviolet spectrum Methods 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241001522878 Escherichia coli B Species 0.000 description 2
- 241000251748 Myxinidae Species 0.000 description 2
- 241001647006 Myxococcus virescens Species 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 235000002725 Olea europaea Nutrition 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- -1 amine acids Chemical class 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- JIDVGUQUQSOHOL-UHFFFAOYSA-N myxin Chemical compound C1=CC=C2[N+]([O-])=C3C(OC)=CC=CC3=[N+]([O-])C2=C1O JIDVGUQUQSOHOL-UHFFFAOYSA-N 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 241000276408 Bacillus subtilis subsp. subtilis str. 168 Species 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- 241000863434 Myxococcales Species 0.000 description 1
- 229910017974 NH40H Inorganic materials 0.000 description 1
- 208000032976 Neuroendocrine carcinoma of pancreas Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241000222481 Schizophyllum commune Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000446764 Shigella dysenteriae 3 Species 0.000 description 1
- 241001532577 Sorangium Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241001342522 Vampyrum spectrum Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- QMMMCTXNYMSXLI-UHFFFAOYSA-N fast blue B Chemical compound C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 QMMMCTXNYMSXLI-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000727 fraction Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 230000023149 myxospore formation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 108010087204 oncoimmunin-M Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000024001 sorocarp development Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000001323 two-dimensional chromatography Methods 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 229940126572 wide-spectrum antibiotic Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
- C07G11/00—Antibiotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Compounds Of Unknown Constitution (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL42701A IL42701A (en) | 1973-07-10 | 1973-07-10 | Antibiotic "ta" |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1039213A true CA1039213A (en) | 1978-09-26 |
Family
ID=11047218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA204,155A Expired CA1039213A (en) | 1973-07-10 | 1974-07-05 | Antibiotic ta from myxococcus xanthus |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US3973005A (enExample) |
| CA (1) | CA1039213A (enExample) |
| CH (1) | CH615221A5 (enExample) |
| GB (1) | GB1477518A (enExample) |
| IL (1) | IL42701A (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4104369A (en) * | 1976-08-31 | 1978-08-01 | State Of Michigan | Lymphosarcin and method of producing lymphosarcin |
| EP0262085A1 (de) * | 1986-08-15 | 1988-03-30 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Antibiotika aus Myxococcus |
| US5532231A (en) * | 1994-11-01 | 1996-07-02 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Antibacterial agent |
| US20040235107A1 (en) * | 1999-01-29 | 2004-11-25 | Ramot At Tel Aviv University Ltd. | Biosynthesis of TA antibiotic |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1800363A1 (de) * | 1967-10-04 | 1969-07-03 | Shionogi & Co | Tsushimycin und seine Herstellung |
-
1973
- 1973-07-10 IL IL42701A patent/IL42701A/en unknown
-
1974
- 1974-06-28 GB GB2893274A patent/GB1477518A/en not_active Expired
- 1974-07-05 CA CA204,155A patent/CA1039213A/en not_active Expired
- 1974-07-05 US US05/485,935 patent/US3973005A/en not_active Expired - Lifetime
- 1974-07-10 CH CH954674A patent/CH615221A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US3973005A (en) | 1976-08-03 |
| GB1477518A (en) | 1977-06-22 |
| CH615221A5 (enExample) | 1980-01-15 |
| IL42701A0 (en) | 1973-10-25 |
| IL42701A (en) | 1977-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stapley et al. | Cephamycins, a new family of β-lactam antibiotics I. Production by Actinomycetes, including Streptomyces lactamdurans sp. n | |
| Berger et al. | A new antibiotic X-5108 of Streptomyces origin I. Production, isolation and properties | |
| US4161523A (en) | Rosamicin esters, acid addition salts and methods for production thereof | |
| Box et al. | Prasinons A and B: Potent insecticides from Streptomyces prasinus | |
| US4042683A (en) | Rifamycins P, Q and U | |
| CA1039213A (en) | Antibiotic ta from myxococcus xanthus | |
| HU188684B (en) | Process for producing a2, and simultaneously produced a1 and a3 components of antibioticum a/16686 | |
| US3960667A (en) | Antibiotic A23187 and process for preparation thereof | |
| US4180564A (en) | A-38533 Antibiotics and process for production thereof | |
| CA1072032A (en) | Antibiotic a-35512b aglycone | |
| US3592925A (en) | Antibiotics ah272alpha2 and ah272beta2 and process for producing same | |
| Kintaka et al. | ISOSULFAZECIN, A NEW β-LACTAM ANTIBIOTIC, PRODUCED BY AN ACIDOPHILIC PSEUDOMONAD FERMENTATION, ISOLATION AND CHARACTERIZATION | |
| US4081531A (en) | Antibiotic mimosamycin | |
| US3454696A (en) | Antibiotics 460 and methods for their production | |
| US4282322A (en) | Process for enzymatic deacylation of antibiotics | |
| US3898327A (en) | Antibiotic azdimycin | |
| US4001397A (en) | Antibiotic compound 41,012 | |
| US5192742A (en) | Compounds and compositions for the treatment of bacterial infections in animals | |
| US4560662A (en) | Streptomyces antibioticus ATCC 31771 and process for obtaining same | |
| US3219530A (en) | Porfiromycin antibiotic and production thereof | |
| CA1220746A (en) | Luzopeptin e.sub.2 | |
| US3061516A (en) | Telomycin and its production | |
| US4127446A (en) | Process for producing antibiotics mimosamycin and chlorocarcins A, B and C | |
| CA1046965A (en) | Naphthyridinomycin antibiotics from streptomyces | |
| US4036696A (en) | Preparation of antibiotics by fermentation |